Atosiban is an inhibitor of the hormones vasopressin and oxytocin. It is used as an intravenous medication as a labor repressant (tocolytic) to halt premature labor. Atosiban is used to delay birth in adult women 24 to 33 weeks pregnant, when they show signs that they may give birth pre-term (prematurely). These signs include regular contractions lasting at least 30 seconds at a rate of at least four every 30 minutes, and dilation of the cervix (the neck of the womb) of 1 to 3 cm, and an effacement (a measure of the thinness of the cervix) of 50% or more.
MARKET DYNAMICS
The atosiban market has shown a significant evolution over the forecast period. The rise of the atosiban market is majorly driven by the increasing prevalence of preterm labor globally. Preterm birth is the leading cause of neonatal morbidity and mortality, is estimated at an incidence of 12.7% of all deliveries. The rising rate of risk factors like diabetes, high blood pressure, being pregnant with more than one baby, being either obese or underweight, several vaginal infections, air pollution including tobacco smoking, and psychological stress is fuelling the market. Moreover, the increasing awareness regarding fetal mortality and morbidity is further boosting the atosiban market growth. Approximately 15 million babies are preterm each year (5% to 18% of all deliveries). In the United Kingdom, there are about 7.9%, and in the United States, they are about 12.3% of all births. However, adverse side effects of the medication are likely to impede the growth of the atosiban market.
MARKET SCOPE
The "Atosiban Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry's pharmaceuticals, with a specific focus on the global market trend analysis. This report outlines the atosiban market with detailed market segmentation by type, application, and end-user. The atosiban market is estimated to witness a high rise during the forecast period. It focuses on the vital statistics on the leading players' market status in the atosiban market and provides key opportunities and trends in the market.
MARKET SEGMENTATION
The market is categorized based on the type, application, and end user. Based on the type, the market is segmented as injection and concentrate. Based on the application, the segmentation of the market is into suppression of preterm labor and others. Based on end user, the segmentation of the market is into hospitals, clinics, and others.
REGIONAL FRAMEWORK
The report states a detailed outline of the industry, consisting of both quantitative and qualitative information. It offers a sketch and forecast of the atosiban market based on various segments. The report also consists of market size and forecast estimates from the year 2020 to2028with respect to five main regions, namely; North America, Asia-Pacific (APAC), Europe, Middle East, and Africa (MEA), and South & Central America (SCAM). The atosiban market by each region is then sub-segmented into respective countries and segments. It comprises the analysis and forecast of 18 countries globally and the recent trend and opportunities prevailing in the region.
The report analyzes factors affecting the atosiban market from both the demand and supply sides. Furthermore, it evaluates market dynamics regarding the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends. It also consists of precise PEST analysis for all five regions, namely, North America, Asia Pacific, Europe, Middle East and Africa, and South & Central America, after assessing political, social, economic, and technological factors affecting the Atosiban market in these regions.
MARKET PLAYERS
The report contains critical developments in the atosiban market as inorganic and organic growth strategies. Several companies are pivoting on organic growth strategies like product launches, product approvals, and others, such as patents and events. Inorganic growth strategies observed were collaborations and acquisitions &partnerships. Various such activities have paved the path for elaborating the business and customer base of market players. The market players from the atosiban market are estimated to have profitable growth opportunities in the coming years with the higher demand for atosiban in the global market. Given below is the list of a few companies engaged in the atosiban market.
The report also offers key players' profiles in the atosiban market, along with their SWOT analysis and market strategies. Also, the report focuses on the key market players with information on company profiles, financial information of the last three years, components, and services provided, critical development in the past five years.
-Ferring Pharmaceuticals
-Sun Pharmaceutical Industries
-Shanghai Soho-Yiming Pharmaceuticals Co.,Ltd.
-EVER NEURO PHARMA GMBH
-Hangzhou Longshine Bio-Tech Co.,LTD.
-Cayman Chemical.
-Hemmo Pharmaceuticals Pvt Ltd
-GlaxoSmithKline plc.
The Insight Partner's dedicated research and the analytical team comprises of experienced professionals with advanced statistical expertise and offers several customization options in the current report.